Search

everythinglearnresearchcommunity

for

Search:↓

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Some patients on immunosuppressants had a weaker immune response to the Sinovac-CoronaVac COVID-19 vaccine.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

There is no gold standard treatment for hidradenitis suppurativa due to insufficient evidence.

Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Vaccination is crucial for psoriasis patients on immunosuppressive therapy to manage COVID-19 risks.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.

Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Hidradenitis Suppurativa is likely an autoinflammatory disease, and better understanding its causes could improve treatments.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

Skin issues can indicate immune system problems.

Alopecia areata causes hair loss, has no cure, and various treatments exist.